Cargando…

A validated nomogram integrating hematological indicators to predict response to neoadjuvant therapy in esophageal squamous cell carcinoma patients

BACKGROUND: The prognoses for advanced Esophageal squamous cell cancer (ESCC) was very poor. Neoadjuvant therapy was shown to improve overall survival of ESCC patients. However, there is still no effective indicator to predict the efficacy of neoadjuvant therapy. The present study intended to invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Sichao, Zhou, Zihao, Tian, Dan, Huang, Shujie, Wang, Ce, Gao, Zhen, Ben, Xiaosong, Tang, Jiming, Xie, Liang, Zhou, Haiyu, Zhang, Dongkun, Shi, Ruiqing, Deng, Cheng, Zhuang, Weitao, Ding, Yu, Qiao, Guibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106100/
https://www.ncbi.nlm.nih.gov/pubmed/33987401
http://dx.doi.org/10.21037/atm-21-1628
_version_ 1783689716155023360
author Wang, Sichao
Zhou, Zihao
Tian, Dan
Huang, Shujie
Wang, Ce
Gao, Zhen
Ben, Xiaosong
Tang, Jiming
Xie, Liang
Zhou, Haiyu
Zhang, Dongkun
Shi, Ruiqing
Deng, Cheng
Zhuang, Weitao
Ding, Yu
Qiao, Guibin
author_facet Wang, Sichao
Zhou, Zihao
Tian, Dan
Huang, Shujie
Wang, Ce
Gao, Zhen
Ben, Xiaosong
Tang, Jiming
Xie, Liang
Zhou, Haiyu
Zhang, Dongkun
Shi, Ruiqing
Deng, Cheng
Zhuang, Weitao
Ding, Yu
Qiao, Guibin
author_sort Wang, Sichao
collection PubMed
description BACKGROUND: The prognoses for advanced Esophageal squamous cell cancer (ESCC) was very poor. Neoadjuvant therapy was shown to improve overall survival of ESCC patients. However, there is still no effective indicator to predict the efficacy of neoadjuvant therapy. The present study intended to investigate the correlation between hematological parameters and the efficacy of neoadjuvant therapy so as to provide a reference for the prediction of cancer response to neoadjuvant therapy. METHODS: This study included 197 ESCC patients in our center from January 2010 to December 2018. Response evaluation criteria in solid tumors (RECIST) criteria were used for the treatment evaluation. The results of univariate and multivariate logistic regression analysis were used to select independent factors for construction of the prediction model. The concordance index (C-index), receiver operating characteristic (ROC) curve, and calibration curve were used to evaluate the robustness of the model, while the bootstrap method was used for internal validation. RESULTS: Among the 197 included ESCC patients, 94 patients achieved partial remission, 80 patients were in stable condition, and 23 patients had disease progression, 123 of whom underwent surgery. The comparisons of the dynamic hematological test results before and after treatment show that pre-PLT, pre-MONO%, post-Hb, △WBC, and the option of undergoing neoadjuvant chemoradiation were the potential predictors for the effectiveness of neoadjuvant therapy. The model in which the C-index was 0.803 (95% confidence interval: 0.742–0.864) showed good prediction performance, and still reach a C-index of 0.764 when internally validated. CONCLUSIONS: For the neoadjuvant treatment of ESCC, hematological indexes are closely related to the efficacy of neoadjuvant therapy. The nomogram can be used to easily predict the efficacy of neoadjuvant therapy in patients.
format Online
Article
Text
id pubmed-8106100
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-81061002021-05-12 A validated nomogram integrating hematological indicators to predict response to neoadjuvant therapy in esophageal squamous cell carcinoma patients Wang, Sichao Zhou, Zihao Tian, Dan Huang, Shujie Wang, Ce Gao, Zhen Ben, Xiaosong Tang, Jiming Xie, Liang Zhou, Haiyu Zhang, Dongkun Shi, Ruiqing Deng, Cheng Zhuang, Weitao Ding, Yu Qiao, Guibin Ann Transl Med Original Article BACKGROUND: The prognoses for advanced Esophageal squamous cell cancer (ESCC) was very poor. Neoadjuvant therapy was shown to improve overall survival of ESCC patients. However, there is still no effective indicator to predict the efficacy of neoadjuvant therapy. The present study intended to investigate the correlation between hematological parameters and the efficacy of neoadjuvant therapy so as to provide a reference for the prediction of cancer response to neoadjuvant therapy. METHODS: This study included 197 ESCC patients in our center from January 2010 to December 2018. Response evaluation criteria in solid tumors (RECIST) criteria were used for the treatment evaluation. The results of univariate and multivariate logistic regression analysis were used to select independent factors for construction of the prediction model. The concordance index (C-index), receiver operating characteristic (ROC) curve, and calibration curve were used to evaluate the robustness of the model, while the bootstrap method was used for internal validation. RESULTS: Among the 197 included ESCC patients, 94 patients achieved partial remission, 80 patients were in stable condition, and 23 patients had disease progression, 123 of whom underwent surgery. The comparisons of the dynamic hematological test results before and after treatment show that pre-PLT, pre-MONO%, post-Hb, △WBC, and the option of undergoing neoadjuvant chemoradiation were the potential predictors for the effectiveness of neoadjuvant therapy. The model in which the C-index was 0.803 (95% confidence interval: 0.742–0.864) showed good prediction performance, and still reach a C-index of 0.764 when internally validated. CONCLUSIONS: For the neoadjuvant treatment of ESCC, hematological indexes are closely related to the efficacy of neoadjuvant therapy. The nomogram can be used to easily predict the efficacy of neoadjuvant therapy in patients. AME Publishing Company 2021-04 /pmc/articles/PMC8106100/ /pubmed/33987401 http://dx.doi.org/10.21037/atm-21-1628 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Wang, Sichao
Zhou, Zihao
Tian, Dan
Huang, Shujie
Wang, Ce
Gao, Zhen
Ben, Xiaosong
Tang, Jiming
Xie, Liang
Zhou, Haiyu
Zhang, Dongkun
Shi, Ruiqing
Deng, Cheng
Zhuang, Weitao
Ding, Yu
Qiao, Guibin
A validated nomogram integrating hematological indicators to predict response to neoadjuvant therapy in esophageal squamous cell carcinoma patients
title A validated nomogram integrating hematological indicators to predict response to neoadjuvant therapy in esophageal squamous cell carcinoma patients
title_full A validated nomogram integrating hematological indicators to predict response to neoadjuvant therapy in esophageal squamous cell carcinoma patients
title_fullStr A validated nomogram integrating hematological indicators to predict response to neoadjuvant therapy in esophageal squamous cell carcinoma patients
title_full_unstemmed A validated nomogram integrating hematological indicators to predict response to neoadjuvant therapy in esophageal squamous cell carcinoma patients
title_short A validated nomogram integrating hematological indicators to predict response to neoadjuvant therapy in esophageal squamous cell carcinoma patients
title_sort validated nomogram integrating hematological indicators to predict response to neoadjuvant therapy in esophageal squamous cell carcinoma patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106100/
https://www.ncbi.nlm.nih.gov/pubmed/33987401
http://dx.doi.org/10.21037/atm-21-1628
work_keys_str_mv AT wangsichao avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT zhouzihao avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT tiandan avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT huangshujie avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT wangce avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT gaozhen avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT benxiaosong avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT tangjiming avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT xieliang avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT zhouhaiyu avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT zhangdongkun avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT shiruiqing avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT dengcheng avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT zhuangweitao avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT dingyu avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT qiaoguibin avalidatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT wangsichao validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT zhouzihao validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT tiandan validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT huangshujie validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT wangce validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT gaozhen validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT benxiaosong validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT tangjiming validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT xieliang validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT zhouhaiyu validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT zhangdongkun validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT shiruiqing validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT dengcheng validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT zhuangweitao validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT dingyu validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients
AT qiaoguibin validatednomogramintegratinghematologicalindicatorstopredictresponsetoneoadjuvanttherapyinesophagealsquamouscellcarcinomapatients